Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6531
    +0.0031 (+0.48%)
     

  • OIL

    82.96
    +0.15 (+0.18%)
     

  • GOLD

    2,341.50
    +3.10 (+0.13%)
     

  • Bitcoin AUD

    97,945.00
    -3,841.38 (-3.77%)
     

  • CMC Crypto 200

    1,357.06
    -25.51 (-1.85%)
     

  • AUD/EUR

    0.6091
    +0.0021 (+0.35%)
     

  • AUD/NZD

    1.0955
    +0.0013 (+0.12%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,090.22
    +49.84 (+0.62%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,954.44
    -134.26 (-0.74%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Company News For Nov 12, 2019

Zacks Equity Research

  • Qurate Retail Inc.’s QRTEA shares jumped 11.4% after the company reported third-quarter 2019 adjusted earnings per share of $0.42, beating the Zacks Consensual Estimate of $034.

  • Amicus Therapeutics Inc. FOLD surged 3.8% after the company posted third-quarter 2019 total revenue of $48.8 million, surpassing the Zacks Consensus Estimate of $48.1 million.

  • Shares of Nektar Therapeutics NKTR soared 4.7% following positive clinical trial data of its drug NKTR-358 to treat autoimmune and inflammatory diseases.

  • Walgreens Boots Alliance Inc. WBA shares climbed 5.1% following news that KKR & Co. Inc. KKR has decided to acquire the drugstore giant.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
KKR & Co. Inc. (KKR) : Free Stock Analysis Report
 
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
 
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
 
Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
 
Qurate Retail Group, Inc. (QRTEA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research